

# What is the evidence base for the assessment and management of cancer cachexia in adults with incurable pancreatic cancer?

## Included Studies:

Bourdel-Marchasson I, Blanc-Bisson C, Doussau A, Germain C, Blanc J F, Dauba J, Lahmar C, Terrebbonne E, Lecaillon C, Ceccaldi J, Cany L, Lavau-Denes S, Houede N, Chomy F, Durrieu J, Soubeyran P, Senesse P, Chene G, Fonck M. Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: A two-year randomized controlled trial. *PLoS ONE*. 2014; 9.

Golan T, Geva R, Richards D, Madhusudan S, Lin B K, Wang HT, Walgren RA, Stemmer SM. LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. *Journal of Cachexia, Sarcopenia and Muscle*. 2018; 9:871-879.

Kays JK, Shahda S, Stanley M, Bell TM, O'Neill BH, Kohli MD, Couch ME, Koniaris LG, Zimmers TA. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. *Journal of Cachexia, Sarcopenia and Muscle*. 2018; 4: 673-684.

Kraft M, Kraft K, Gartner S, Mayerle J, Simon P, Weber E, Schutte K, Stieler J, Koula-Jenik H, Holzhauser P, Grober U, Engel G, Muller C, Feng YS, Aghdassi A, Nitsche C, Malfertheiner P, Patrzyk M, Kohlmann T, Lerch MM. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - A randomized multicentre trial. *Nutrition Journal*. 2012; 11.

Kurita Y, Kobayashi N, Tokuhisa M, Goto A, Kubota K, Endo I, Nakajima A, Ichikawa Y. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. *Pancreatology*. 2019; 19: 127-135.

Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, Dessì M, Panzone F, Contu P. Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia. *The Oncologist*. 2010;15:200-211.

Park I, Choi S J, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Prognostic factors for risk stratification of patients with recurrent or metastatic pancreatic adenocarcinoma who were treated with gemcitabine-based chemotherapy. 2016; 48:1264-1273.

Pelzer U, Arnold D, Govercin M, Stieler J, Doerken B, Riess H, Oettle H. Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. *BMC Cancer*. 2010; 10: 86.

Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, Baracos VE. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? *American Journal of Clinical Nutrition*. 2013; 98:1012-1019.

## Other References:

1. Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol*. 12, 489–495 (2011).
2. Arends, J. et al. ESPEN guidelines on nutrition in cancer patients. *Clin. Nutr*. 36, 11–48 (2017).
3. Martin, L. et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. *J. Clin. Oncol*. 31, 1539–1547 (2013).
4. Grande AJ, et al. Exercise for cancer cachexia in adults. *Cochrane Database Syst Rev* 2014; Cd010804.

## Additional materials available upon request:

- Critical appraisal / data extraction forms
- Search strategies
- List of excluded studies

**This report should be cited as follows:** Palliative Care Evidence Review Service. A rapid review: What is the evidence base for the assessment and management of cancer cachexia in adults with incurable pancreatic cancer? Cardiff: Palliative Care Evidence Review Service (PaCERS); 2019 February.

**Permission Requests:** All inquiries regarding permission to reproduce any content of this review should be directed to [PaCERSWCRC@cardiff.ac.uk](mailto:PaCERSWCRC@cardiff.ac.uk)

**Disclaimer:** Palliative Care Evidence Review Service (PaCERS) is an information service for those involved in planning and providing palliative care in Wales. Rapid reviews are based on a limited literature search and are not comprehensive, systematic reviews. This review is current as of the date of the literature search specified in the Review Methods section. PaCERS makes no representation that the literature search captured every publication that was or could be applicable to the subject matter of the report.